Lataa...
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have assembled the evidence related to the efficacy and safety of these...
Tallennettuna:
| Julkaisussa: | Front Oncol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6333640/ https://ncbi.nlm.nih.gov/pubmed/30687633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00557 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|